IVA Key Statistics, Chart & Performance
The current stock price of IVA is 4.35 USD. In the past month the price increased by 1.16%. In the past year, price increased by 64.15%.
IVA Latest News, Press Relases and Analysis
IVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About IVA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121 FR
CEO: Frederic Cren
Employees: 116
Phone: 33380447500
INVENTIVA SA - ADR / IVA FAQ
What does INVENTIVA SA - ADR do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the stock price of INVENTIVA SA - ADR today?
The current stock price of IVA is 4.35 USD. The price increased by 2.35% in the last trading session.
What is the dividend status of INVENTIVA SA - ADR?
IVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IVA stock?
IVA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the growth outlook for INVENTIVA SA - ADR?
The Revenue of INVENTIVA SA - ADR (IVA) is expected to decline by -14.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for INVENTIVA SA - ADR?
INVENTIVA SA - ADR (IVA) has a market capitalization of 830.93M USD. This makes IVA a Small Cap stock.
When does INVENTIVA SA - ADR (IVA) report earnings?
INVENTIVA SA - ADR (IVA) will report earnings on 2026-02-16, after the market close.
IVA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 86.52% of all stocks.
IVA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IVA. IVA may be in some trouble as it scores bad on both profitability and health.
IVA Financial Highlights
Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS decreased by -74.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.84% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA Forecast & Estimates
13 analysts have analysed IVA and the average price target is 13.74 USD. This implies a price increase of 215.83% is expected in the next year compared to the current price of 4.35.
For the next year, analysts expect an EPS growth of 38.93% and a revenue growth -14.87% for IVA